Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-04-26 am EDT			5-day change	1st Jan Change
947.4 ^INR	-0.40%		+2.74%	+37.46%

Apr. 26	Weak March Quarter Earnings Weigh Down Indian Equities on Friday	MT
Apr. 26	Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	MT

Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.

March 15, 2024 at 06:17 am EDT

From February 9, 2024 to March 6, 2024, the company has repurchased 5,970,149 shares, representing 0.59% for INR 6,000 million. With this, the company has completed the repurchase of 5,970,149 shares, representing 0.59% for INR 6,000 million under the buyback announced on February 9, 2024.

Latest news about Zydus Lifesciences Limited

Weak March Quarter Earnings Weigh Down Indian Equities on Friday	Apr. 26	MT
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	Apr. 26	MT
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	Apr. 24	MT
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	Apr. 23	CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	Apr. 22	CI
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	Apr. 21	MT
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	Apr. 21	MT
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	Apr. 01	CI
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	Mar. 28	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	Mar. 23	CI
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	Mar. 17	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	Mar. 16	CI
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	Mar. 15	CI
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	Mar. 14	MT
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	Mar. 14	CI
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	Mar. 14	CI
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	Mar. 13	MT
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib	Mar. 13	CI
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection	Mar. 11	MT
Zydus Lifesciences Limited's Equity Buyback announced on February 9, 2024, has closed with 5,970,149 shares, representing 0.59% for INR 6,000 million.	Mar. 05	CI
Zydus Lifesciences Forms UAE-Based Arm	Feb. 22	MT
Zydus Lifesciences Limited Announces Incorporation of Wholly Owned Subsidiary Company	Feb. 22	CI
Zydus Lifesciences Gets US FDA Final Approval for Generic Chest Pain Drug	Feb. 16	MT

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

947.4 INR

Average target price

844.6 INR

Spread / Average Target

-10.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-4.29%	4.71B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.

EPS Revisions